Netupitant ‐ Palonosetron FDC Market Growing at a CAGR of 10.8% to Reach $527,187 million by 2022

Netupitant Palonosetron Market Report, published by Allied Market Research, was valued at $257,162 million in 2015, and is expected to reach $527,187 million by 2022, growing at a CAGR of 10.8% from 2016 to 2022.

Netupitantpalonosetron FDC market holds a substantial scope for growth globally. The market is in its growth stage; however, its contribution to the global market is expected to increase significantly within the next six years.High cost is a major limitation to for the growth of the market in developing regions. However, recent innovations, which embed high potential and longer duration of action within the CINV drugs reach a wider segment of audiences. Numerous players are stepping in the CINV market with innovative products. Emerging technology such as novel drugs discovery and innovation of antiemetic therapy are expected to increase the competition in the near future.

KEY FINDINGS OF NETUPITANT - PALONOSETRON MARKET:
• North America dominated the netupitantpalonosetron market, and is expected to grow at a CAGR of 9.9%.
• Asia-Pacific shows thehighestgrowthrate, and is estimated to grow at a CAGR of 14.7%.

Get sample copy with statistical info of this report @
https://www.alliedmarketresearch.com/request-sample/1831

Advancement in technology to discover new high-potential FDC drug

Companies seek technological advancement to lower production cost and to discover new products. For instance, new drug named rolapitant (Varubi) is developed using new technology by Tesaro, a healthcare-based company. It is the company's first product under CINV drugs segment, which gained significant traction in the netupitant‐palonosetron FDC drug market.

Approval of new drugs provides cancer patients with effective treatment for prevention of delayed phase of nausea and vomiting caused by chemotherapy. This is attributed to increase the demand for netupitant‐palonosetron FDC drugs during the forecast period.

Geographically, North America was the dominant regional market for netupitant‐palonosetron FDC drugs, in terms of revenue, due to growth in incidence of CINV among patients. These drugs are expected to have significant impact on the revenue of the overall market. Approval of new drugs such as rolapitant and Sustol (APF-530) is expected to boost the growth of the CINV drugs in the US market during the forecast period. Europe was the second largest regional market for netupitant‐palonosetron FDC drugs, in terms of revenue, due to growth in demand for netupitant‐palonosetron FDC drugs among patients.

Top Key Players :

• Acacia Pharma
• Helsinn Holding S.A.
• Heron Therapeutics Inc.
• Eisai Pharmaceutical Pvt Ltd

Purchase this exclusive report @
https://www.alliedmarketresearch.com/purchase-enquiry/1831

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

Sona Padman
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.